ARA-290 research: what the published studies show

Origin and Design

A 2008 study set out to narrow erythropoietin's tissue-protective activity down to short sequences, and it describes the hormone's two functions as running through different receptors.^[1] Blood cell production runs through the erythropoietin receptor homodimer, and tissue protection through a heterocomplex of that receptor with CD131, the beta common receptor.^[1] Helix B, residues 58 to 82, was tissue protective.^[1]

An 11-amino-acid peptide made of the adjacent residues forming the aqueous face of helix B was also tissue protective.^[1]It showed benefit in models of ischemic stroke and of renal ischemia-reperfusion, accelerated wound healing and augmented cognitive function in rodents.^[1] Neither helix B nor the 11-residue peptide was erythropoietic in vitro or in vivo.^[1] That paper predates the names ARA-290 and cibinetide, and the product specification identifies this compound as that 11-residue peptide.

Nerve Injury Pain in Rats

A 2014 study used a rat spared-nerve-injury model with dosing on days 1, 3, 6, 8 and 10.^[2] Mechanical allodynia was significantly reduced against vehicle for up to 20 weeks, with a dose-response relationship.^[2] Cold allodynia was significantly reduced up to 20 weeks at 3, 10, 30 and 60 micrograms per kilogram.^[2]

The same study looked at spinal glial responses at 2 and 20 weeks.^[2] At 2 weeks, vehicle animals showed significant microglial reactivity in the L5 spinal segment while animals given 10 or 30 micrograms per kilogram did not.^[2] At 20 weeks, more widespread microglial reactivity appeared in animals given vehicle or 10 micrograms per kilogram, so the dose that held at 2 weeks did not hold at 20.^[2]

Sarcoidosis-Associated Small Fiber Neuropathy

A double-blind placebo-controlled pilot enrolled 22 patients with sarcoidosis and symptoms of small fiber neuropathy, given 2 mg intravenously three times weekly for four weeks or placebo.^[3] No safety concerns arose on clinical or laboratory assessment.^[3] The symptom score improved significantly against placebo at week 4, by 11.5 points against 2.9, and the pain and physical functioning dimensions of the SF-36 changed significantly from baseline.^[3]Two measures did not separate.^[3] Brief Pain Inventory and Fatigue Assessment Scale scores improved significantly but equivalently in both groups.^[3] No change was seen on the Inventory of Depressive Symptomatology.^[3] The authors state the peptide appears safe in this population and can reduce neuropathic symptoms.^[3]

A phase 2b trial then ran 28 days in 64 subjects with sarcoid-associated small nerve fiber loss and neuropathic pain, comparing 1, 4 and 8 mg per day with placebo.^[4] The primary endpoint was change in corneal nerve fiber area.^[4] The placebo-corrected mean change in that area was 109 square micrometres at 1 mg and 431 at 8 mg, with confidence intervals spanning zero in both.^[4] At 4 mg it was 697, with P equal to 0.012.^[4] Only the middle dose reached significance.^[4]

Regenerating intraepidermal fibers increased in the 4 mg group, and changes in corneal nerve fiber area correlated with that measure and with six-minute walk distance.^[4] Pain improved significantly in all groups, including placebo.^[4] Among subjects with moderate to severe pain, the placebo-corrected fall in pain intensity in the 4 mg group did not reach significance, at P equal to 0.157.^[4] The authors describe the nerve fiber result as consistent with a disease-modifying effect.^[4]

Diabetic Macular Edema

A phase 2 trial gave 4 mg daily by subcutaneous self-administration for 12 weeks to patients with untreated diabetic macular edema.^[5] There was no change in best corrected visual acuity, central retinal thickness, central retinal sensitivity or tear production, while a composite visual function questionnaire score improved by 2.7 points.^[5] Some participants showed improvements in retinal thickness, tear production, diabetic control and albuminuria.^[5]

No serious adverse events, no adverse reactions and no anti-cibinetide antibodies were seen, and the authors conclude the course was safe and the scattered improvements warrant further investigation.^[5] On its stated primary and secondary measures this trial was negative.^[5]

State of the Evidence

Roughly 150 records are indexed across the names ARA 290, ARA290 and cibinetide. Five are cited here. Human evidence exists and is at phase 2, which is further than most compounds in this catalog reach, and it is also mixed.

Two results should be read together. The corneal nerve fiber endpoint reached significance at one of three doses and not at the two either side of it.^[4] The same trial found pain improving in every group including placebo, and the placebo-corrected pain difference did not reach significance.^[4] A nerve-structure change and a symptom change are not the same claim.

Authorship is concentrated. Michael Brines and Anthony Cerami are authors of the paper that introduced the peptide.^[1]Both are also authors of the rat pain study.^[2] Albert Dahan appears on the rat study, the sarcoidosis pilot and the phase 2b trial.^[4] The diabetic macular edema trial comes from an unrelated group and is the least favorable result on this page.^[5]

One paper in this field has been retracted. A 2012 study of pyroglutamate helix B surface peptide in acute kidney injury was retracted in February 2026 and is not cited here. Any renal claim about this compound needs a source that is not that paper.

Nothing here is extrapolated from the parent. Erythropoietin is a glycoprotein hormone with a large clinical literature, and this is an eleven-residue peptide designed to reproduce one part of its structure. Only work on the peptide appears above.